



## **Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting**

**SAN DIEGO – November 27, 2017** – Impact Biomedicines today announced that retrospective data on fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV), will be presented in a poster at the 59<sup>th</sup> American Society of Hematology (ASH) Annual Meeting, taking place on December 9-12, 2017 in Atlanta, GA.

The details of the presentation are as follows:

**Session:** 634 – Myeloproliferative Syndromes: Clinical: Poster III

**Poster Title:** Case Series of Potential Wernicke’s Encephalopathy in Patients treated with Fedratinib

**Presenter:** John Hood, Ph.D.

**Date:** Monday, December 11, 2017

**Presentation time:** 6:00-8:00 PM ET

**Location:** Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

### **About Impact Biomedicines**

Impact Biomedicines (“Impact”) is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule, JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV).

### **Media Contact:**

Cammy Duong

MacDougall Biomedical Communications

781-591-3443

[cduong@macbiocom.com](mailto:cduong@macbiocom.com)